Macrophages: Important players in primary Sjögren's syndrome?

Expert Review of Clinical Immunology

Volumn 10, Issue 4, 2014, Pages 513-520

  Zhou, Delu ^a   McNamara, Nancy A ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

clodronate liposome; dry eye disease; IFN ; IL 1 receptor antagonist; IL 1 ; keratoconjunctivitis sicca; macrophages; primary Sj grens syndrome; squamous metaplasia

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; DISEASE SEVERITY; DRY EYE; HUMAN; IMMUNOPATHOGENESIS; KERATOCONJUNCTIVITIS SICCA; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MACROPHAGE FUNCTION; MONOCYTE; NONHUMAN; REVIEW; SALIVARY GLAND BIOPSY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SQUAMOUS CELL METAPLASIA; TARGET ORGAN;

ANIMALS; HUMANS; MACROPHAGES; SJOGREN'S SYNDROME;

EID: 84896961095     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.900441     Document Type: Review

References (40)

1. Li S, Nikulina K, DeVoss J, et al. Small proline-rich protein 1B (SPRR1B) is a biomarker for squamous metaplasia in dry eye disease. Invest Ophthalmol Vis Sci 2008;49:34-41
2. Zeher M, Adany R, Nagy G, et al. Macrophage containing factor XIII subunit a in salivary glands of patients with Sjogren's syndrome. J Investig Allergol Clin Immunol 1991;1:261-5
3. Tominaga M, Migita K, Sano H, et al. Expression of cyclooxygenase-1 (COX-1) in labial salivary glands of Sjogren's syndrome. Clin Exp Immunol 2000;122:459-63
4. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2012;34:400-7
5. Manoussakis MN, Boiu S, Korkolopoulou P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007:56:3977-88
6. van Blokland SC, Wierenga-Wolf AF, van Helden-Meeuwsen CG, et al. Professional antigen presenting cells in minor salivary glands in Sjogren's syndrome: potential contribution to the histopathological diagnosis? Lab Invest 2000;80:1935-41
7. Fujiwara K, Sakaguchi N, Watanabe T. Sialoadenitis in experimental graft-versus-host disease. An animal model of Sjogren's syndrome. Lab Invest 1991;65: 710-18
8. Jabs DA, Prendergast RA. Murine models of Sjogren's syndrome. Immunohistologic analysis of different strains. Invest Ophthalmol Vis Sci 1988;29:1437-43
9. Chen YT, Li S, Nikulina K, et al. Immune profile of squamous metaplasia development in autoimmune regulator-deficient dry eye. Mol Vis 2009;15:563-76
10. DeVoss JJ, LeClair NP, Hou Y. An autoimmune response to odorant binding protein 1a is associated with dry eye in the Aire-deficient mouse. J Immunol 2010;184: 4236-46
11. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 2002;298:1395-401
12. Devoss JJ, Shum AK, Johannes KP, et al. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J Immunol 2008;181:4072-9
13. Zhou D, Chen YT, Chen F, et al. Critical involvement of macrophage infiltration in the development of Sjogren's syndrome-associated dry eye. Am J Pathol 2012;181:753-60
14. Kuroda N, Mitani T, Takeda N, et al. Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice. J Immunol 2005;174:1862-70
15. Donate A, Voigt A, Nguyen CQ. The value of animal models to study immunopathology of primary human Sjogren's syndrome symptoms. Expert Rev Clin Immunol 2014;10(4):469-81
16. Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. ScientificWorldJournal 2011;11:2391-402
17. Baban B, Liu JY, Abdelsayed R, Mozaffari MS. Reciprocal relation between GADD153 and Del-1 in regulation of salivary gland inflammation in Sjogren syndrome. Exp Mol Pathol 2013;95:288-97
18. Solomon A, Dursun D, Liu Z, et al. Proand anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42:2283-92
19. Chen YT, Lazarev S, Bahrami AF, et al. Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjogren's syndrome. Lab Invest 2012;92:556-70
20. Chen YT, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren's syndrome. Am J Pathol 2010;177:1333-43
21. Li S, Gallup M, Chen YT, McNamara NA. Molecular mechanism of proinflammatory cytokine-mediated squamous metaplasia in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2010;51:2466-75
22. Chen YT, Chen FY, Vijmasi T, et al. Pax6 downregulation mediates abnormal lineage commitment of the ocular surface epithelium in aqueous-deficient dry eye disease. PLoS One 2013;8:e77286
23. Konttinen YT, Platts LA, Tuominen S, et al. Role of nitric oxide in Sjogren's syndrome. Arthritis Rheum 1997;40:875-83
24. Beauregard C, Brandt PC, Chiou GC. Induction of nitric oxide synthase and over-production of nitric oxide by interleukin-1beta in cultured lacrimal gland acinar cells. Exp Eye Res 2003;77:109-14
25. Vijmasi T, Chen FY, Chen YT, et al. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Mol Vis 2013;19: 1957-65
26. Greenwell-Wild T, Moutsopoulos NM, Gliozzi M, et al. Chitinases in the salivary glands and circulation of patients with Sjogren's syndrome: macrophage harbingers of disease severity. Arthritis Rheum 2011;63:3103-15
27. Gliozzi M, Greenwell-Wild T, Jin W, et al. A link between interferon and augmented plasmin generation in exocrine gland damage in Sjogren's syndrome. J Autoimmun 2012;40:122-33
28. Syrovets T, Lunov O, Simmet T. Plasmin as a proinflammatory cell activator. J Leukoc Biol 2012;92:509-19
29. Li X, Wu K, Edman M, et al. Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse. Invest Ophthalmol Vis Sci 2010;51:5019-29
30. Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 2004;31:96-101
31. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6
32. Wang H, Peters T, Sindrilaru A, Scharffetter-Kochanek K. Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 2009;129: 1100-14
33. Solomon S, Rajasekaran N, Jeisy-Walder E, et al. A crucial role for macrophages in the pathology of K/B x N serum-induced arthritis. Eur J Immunol 2005;35:3064-73
34. Nikolic T, Geutskens SB, van Rooijen N, et al. Dendritic cells and macrophages are essential for the retention of lymphocytes in (peri)-insulitis of the nonobese diabetic mouse: a phagocyte depletion study. Lab Invest 2005;85:487-501
35. Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29: 1412-18
36. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87
37. Nakayamada S, Saito K, Umehara H, et al. Efficacy and safety of mizoribine for the treatment of Sjogren's syndrome: a multicenter open-label clinical trial. Mod Rheumatol 2007;17:464-9
38. Willeke P, Schluter B, Becker H, et al. Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial. Arthritis Res Ther 2007;9:R115
39. Norheim KB, Harboe E, Goransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome-a double blind, randomised clinical trial. PLoS One 2012;7:e30123
40. Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 2013;131:715-23